Compare Dow Inc (DOW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Zoetis Inc — how do they compare? Dow Inc trades at $28.42 (market cap $20.65B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Dow Inc pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Zoetis Inc for 70 Days on average.
| DOW | ZTS | |
|---|---|---|
Market Cap | $20.65B | $30.20B |
Volume | 14,126,943 | 6,175,327 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $147.53 |
52-Week Low | $20.65 | $69.09 |
Typical Hold Time | 82 Days | 70 Days |
Enterprise Value | $36.34B | $37.76B |
Dividend Yield | 4.9% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.59, up 2.95% today, with a bullish technical signal despite mixed indicators. The stock shows deteriorating fundamentals with negative net income margin (-3.13%) and ROE (-7.86%) in 2025, though recent quarters have beaten EPS expectations. Cash flow trends show operational challenges with declining operating cash flow from $7.5B in 2022 to $1.0B in 2025, offset by increased financing activities.
The outlook remains cautious with analyst consensus at 'Hold' (55.55%) and $34.22 price target offering 20% upside. Key risks include persistent margin pressures, high debt levels (debt-to-asset ratio 29.87% in 2025), and cyclical chemical industry exposure. The dividend yield provides some support, but fundamental improvement is needed for sustained recovery.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
